Table 2.
Tumor response before and after PSM.
| Before PSM | After PSM | |||||
|---|---|---|---|---|---|---|
| TACE+L n=91n, (%) | TACE+L+PD-1 n=75n, (%) | P | TACE+L n=48n, (%) | TACE+L+PD-1 n=48n, (%) | P | |
| CR | 3 (3.3) | 4 (5.3) | 1 (2.1) | 2 (4.2) | ||
| PR | 45 (49.5) | 47 (62.7) | 18 (37.5) | 31 (64.6) | ||
| SD | 20 (22.0) | 11 (14.7) | 12 (25.0) | 7 (14.6) | ||
| PD | 23 (25.3) | 13 (17.3) | 17 (35.4) | 8 (16.7) | ||
| ORR | 48 (52.8) | 51 (68.0) | 0.046 | 19 (39.6) | 33 (66.8) | 0.013 |
PSM, propensity score matching; TACE, transarterial chemoembolization, L, lenvatinib; PD-1, anti-PD-1 blockade; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, overall response rate.